Orchestra BioMed is a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine. The company partners with established market leaders to drive global commercialization of its products, establishing multiple long-term potential revenue streams and supporting further product development. Its current product pipeline was organically developed and features Virtue® Sirolimus-Eluting Balloon (SEB) for the treatment of artery disease, the leading cause of death worldwide, and BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension, the leading contributing risk factor for death worldwide. Orchestra BioMed’s business model optimizes capital efficiency and cash flow by developing therapies with a high probability of success that fulfill a specific need, fit within current clinical workflow and deliver health-economic value. Orchestra BioMed is led by a multi-disciplinary team with a long track record of successful product development.
Location: United States, New York, Town of Niles
Employees: 11-50
Total raised: $34M
Founded date: 2017
Founders name: David Hochman
Founders Related Locations: Ireland, Galway City; United States, New York, New York; United States, New York, Town of Niles; United States, Pennsylvania, New Hope
Investors 2
| Date | Name | Website |
| - | Anthro Ven... | anthrovent... |
| - | Perceptive... | perceptive... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.07.2019 | Series B | $34M | - |
Persons 1
| Date | First Name | Last Name | Title | |||
| - | David | Hochman | Chairman, ... | linkedin.c... | - | - |
Mentions in press and media 11
| Date | Title | Description |
| 12.01.2026 | Haemonetics Acquires Vivasure Medical | Vivasure Medical, a Galway, Ireland-based company advancing novel fully absorbable technology for percutaneous vessel closure, has been acquired by Haemonetics Corporation (NYSE: HAE), a Natick, Massachusetts based global provider of blood ... |
| 09.01.2026 | Galways's Vivasure Medical acquired for up to €185m | Vivasure Medical, the Galway-based medical device company, has been acquired by the NYSE-listed Haemonetics Corporation in a deal worth up to €185m if certain conditions are met. Vivasure develops advanced polymer implants and delivery syst... |
| 13.03.2024 | Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting | - |
| 07.03.2024 | Orchestra BioMed to Participate in Upcoming Investor Conferences | - |
| 06.03.2024 | Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients | - |
| 10.12.2019 | Orchestra BioMed Secures $20 Million Financing Facility from Silicon Valley Bank | NEW YORK, Dec. 10, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc., a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced that it has entered into a $20 million cr... |
| 15.07.2019 | Orchestra BioMed Inks $34M Series B-1 Financing | NEW HOPE, PA, Biomedical innovation company announced it has completed a $34 million Series B-1 financing. >> Click here for more funding data on Orchestra BioMed >> To export Orchestra BioMed funding data to PDF and Excel, ... |
| 15.07.2019 | Orchestra BioMed Raises $34M | NEW HOPE, Pa., July 10, 2019 (GLOBE NEWSWIRE) -- Orchestra BioMed, Inc., a biomedical innovation company providing high-impact solutions for large unmet needs in procedure-based medicine, today announced it has completed a $34 million Serie... |
| 12.07.2019 | Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline | Hot on the heels of inking an international distribution deal with Terumo, Orchestra BioMed has secured $34 million in new funding for its devices aimed at high blood pressure and blocked arteries. The series B-1 raise, and its previous ser... |
| 12.07.2019 | Encore: Orchestra BioMed quickly nets another $34M for its cardiovascular pipeline W h i t e p a p e r Vital Precision for Cost Reduction, QA, and Regulatory Compliance | Hot on the heels of inking an international distribution deal with Terumo, Orchestra BioMed has secured $34 million in new funding for its devices aimed at high blood pressure and blocked arteries. Sponsored by Agilent Technologies How woul... |
Show more